Phase I and pharmacologic study of docetaxel and cisplatin in patients with advanced solid tumors

Journal of Clinical Oncology

Volumn 15, Issue 3, 1997, Pages 1071-1079

  Pronk, L C ^a   Schellens, J H ^a   Planting, A S ^a   van den Bent, M J ^a   Hilkens, P H ^a   van der Burg, M E ^a   de Boer Dennert, M ^a   Ma, J ^a   Blanc, C ^a   Harteveld, M ^a   Bruno, R ^a   Stoter, G ^a   Verweij, J ^a  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOCETAXEL;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIARRHEA; DOSE RESPONSE; DRUG MIXTURE; DRUG TOLERANCE; FEMALE; FEVER; FLUID RETENTION; GRANULOCYTOPENIA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR; VOMITING;

EID: 0031044607     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.3.1071     Document Type: Article

References (34)

1. Rowinsky EK, Donehower RC: The clinical pharmacology and use of antimicrotubule agents in cancer chemotherapeutics. Pharmacol Ther 52:35-84, 1991
2. Gueritte-Voegelein F, Guenard D, Lavelle F, et al: Relationships between the structure of Taxol analogues and their antimitotic activity. J Med Chem 34:992-998, 1991
3. Ringel I, Horwitz SB: Studies with RP 56976 (Taxotere): A semi-synthetic analog of Taxol. J Natl Cancer Inst 83:288-291, 1991
4. Bissery MC, Guenard D, Gueritte-Voegelein F, et al: Experimental antitumor activity of Taxotere (RP 56976, NSC 628503), a Taxol analogue. Cancer Res 51:4845-4852, 1991
5. Harrison S, Dykes D, Sheperd RV, et al: Response of human tumor xenografts to Taxotere. Proc Am Assoc Cancer Res 33:526, 1992 (abstr)
6. Denis JN, Greene AE, Guenard D, et al: A highly efficient practical approach to natural Taxol. J Am Chem Soc 110:5917-5919, 1988
7. Nicoletti MI, Massazza G, Abbott BJ, et al: Taxol and Taxotere antitumor activity on human ovarian carcinoma xenografts. Proc Am Assoc Cancer Res 33:519, 1992 (abstr)
8. Extra JM, Rousseau F, Bruno R, et al: Phase I and pharmacokinetic study of Taxotere (RP56976; NSC 628503) given as a short intravenous infusion. Cancer Res 53:1037-1042, 1993
9. Tomiak E, Piccart MJ, Kerger J, et al: Phase I study of Taxotere (RP 56976, NSC 628503) administered as a 1-hour intravenous infusion on a weekly basis. J Clin Oncol 12:1458-1467, 1993
10. Burris H, Irvin R, Kuhn J, et al: Phase I clinical trial of Taxotere administered as either a 2-hour or 6-hour intravenous infusion every 3 weeks. J Clin Oncol 11:950-958, 1993
11. Bisset D, Setanoians A, Cassidy J, et al: Phase I and pharmacokinetic study of Taxotere (RP 56976) administered as a 24-hour infusion. Cancer Res 53:523-527, 1993
12. Pazdur R, Newman RA, Newman BM, et al: Phase I trial of Taxotere: Five day schedule. J Natl Cancer Inst 84:1781-1788, 1992
13. Aapro MS, Zulian G, Alberto P, et al: Phase I and pharmacokinetic study of RP 56976 in a new ethanol-free formulation of Taxotere. Ann Oncol 3:208, 1992 (suppl 5; abstr)
14. Chevallier B, Fumoleau P, Kerbrat P, et al: Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: A phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer. J Clin Oncol 2:314-322, 1995
15. Seidman AD, Hudis C, Crown JPA, et al: Phase II evaluation of Taxotere as initial chemotherapy for metastatic breast cancer. Proc Am Soc Clin Oncol 12:63, 1993 (abstr)
16. Trudeau M, Eisenhauer E, Lofters W, et al: Phase II study of Taxotere as first line chemotherapy for metastatic breast cancer: A National Cancer Institute of Canada Clinical Trial Group study. Proc Am Soc Clin Oncol 12:64, 1993 (abstr)
17. Ten Bokkel-Huinink WW, Prove AM, Piccart M, et al: A phase II trial with docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer. A study of the EORTC Early Clinical Trials Group. Ann Oncol 6:527-532, 1994
18. Valero V, Esparza L, Holmes F, et al: Phase II study of Taxotere in refractory metastatic breast cancer. Proc Am Soc Clin Oncol 12:96, 1993 (abstr)
19. Cerny T, Kaplan S, Pavlidis N, et al: Docetaxel (Taxotere) is active in non-small cell lung cancer: A phase II trial of the EORTC-Clinical Trials Group. Br J Cancer 70:384-387, 1994
20. Fossella FV, Lee JS, Shin DM, et al: Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer. J Clin Oncol 13:645-651, 1995
21. 2 dose of docetaxel with prednisone premedication for patients with advanced non-small cell lung cancer. Cancer 4:968-972, 1995
22. Catimel G, Verweij J, Mattijsen V, et al: Docetaxel (Taxotere): An active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. Ann Oncol 5:533-537, 1994
23. Sulkes A, Smyth J, Sessa C, et al: Docetaxel (Taxotere) in advanced gastric cancer: Results of a phase II clinical trial. Br J Cancer 70:380-383, 1994
24. Aamdal S, Wolff I, Kaplan S, et al: Taxotere in advanced malignant melanoma: A phase II trial of the EORTC Clinical Trials Group. Eur J Cancer 30A:1061-1064, 1994
25. Van Hoesel QGCM, Verweij J, Catimel G, et al: Phase II study with docetaxel (Taxotere) in advanced soft tissue sarcomas of the adult. Ann Oncol 5:539-542, 1994
26. De Forni M, Rougier P, Adenis A, et al: Phase II study of Taxotere in locally advanced and/or metastatic pancreatic cancer. Ann Oncol 5:509, 1994 (suppl 5; abstr)
27. Brundage MD, Pater JL, Zee B: Assessing the reliability of two toxicity scales: Implications for interpretating toxicity data. J Natl Cancer Inst 85:1138-1148, 1993
28. WHO Handbook for Reporting Results of Cancer Treatment. Offset publication no. 48. Geneva, Switzerland, WHO, 1979, pp 22-26
29. Ma J, Verweij J, Kolker HJ, et al: Pharmacokinetic-dynamic relationship of cisplatin in vitro: Simulation of an i.v. bolus and 3h and 20h infusion. Br J Cancer 69:858-862, 1994
30. Bissett D, Setanoians A, Cassidy J, et al: Phase I and pharmacokinetic study of Taxotere (RP56976) administered as a 24-hour infusion. Cancer Res 53:523-527, 1993
31. Sheiner LB, Beal SL: Pharmacokinetic parameter estimates from several least squares procedures: Superiority of extended least squares. J Pharmacokinet Biopharmaceut 13:185-201, 1985
32. Rowinsky EK, Gilbert MR, McGuire WP, et al: Sequences of Taxol and cisplatin: A phase I and pharmacologic study. J Clin Oncol 9:1692-1703, 1991
33. Hruban RH, Yardley JH, Donehower RC, et al: Taxol toxicity: Epithelial necrosis in the gastrointestinal tract associated with polymerized microtubule accumulation and mitotic arrest. Cancer 63:1944-1950, 1989
34. Verweij J, Clavel M, Chevalier B: Paclitaxel (Taxol) and docetaxel (Taxotere): Not simply two of a kind. Ann Oncol 5:495-504, 1994